Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement

Pediatric Nephrology

Volumn 29, Issue 6, 2014, Pages 1103-1106

  Hu, Hushi ^a   Nagra, Arvind ^a   Haq, Mushfequr R ^a   Gilbert, Rodney D ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; DIGOXIN; ECULIZUMAB; HAPTOGLOBIN; LACTATE DEHYDROGENASE; LORAZEPAM; UREA; MONOCLONAL ANTIBODY;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CASE REPORT; CHILD; CONSCIOUSNESS LEVEL; CONTINUOUS HEMOFILTRATION; DIARRHEA; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ERYTHROCYTE CONCENTRATE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOTENSION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; TACHYCARDIA; TONIC CLONIC SEIZURE; VOMITING; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CARDIOMYOPATHY, DILATED; COMPLICATION; INFANT; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; SEIZURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; INFANT; RENAL DIALYSIS; RENAL INSUFFICIENCY; SEIZURES;

EID: 84901622015     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2709-z     Document Type: Article

References (15)

1. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey M-A, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber L, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing adults and children. Clin J Am Soc Nephrol 8:554-562
2. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643-657
3. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med 368:2169-2181
4. Alexia Pharma UK Ltd submission - Eculizumab for aHUS, http://www.specialisedservices.nhs.uk/document/eculizumab-treatment-atypical- haemolytic-uraemic-syndrome/
5. Wong EK, Goodship TH, Kavanagh D (2013) Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 56: 199-212
6. Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323-2326
7. Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH (2013) Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B. Pediatr Nephrol 28:1315-1318
8. Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G (2012) Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 27:2327-2331
9. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M (2012) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59:707-710
10. Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O (2013) Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 28:827-830
11. Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F (2013) Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 28: 155-158
12. Gilbert RD, Stanley LK, Fowler DJ, Angus EM, Hardy SA, Goodship TH (2013) Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab. Clin Kidney J 6:421-425
13. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-Toxin - Associated HUS. N Engl J Med 364:2561-2563
14. Ohanian M, Cable C, Halka K (2011) Management of hemolytic uremic syndrome. Clin Pharmacol 3:5-12
15. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45:531-536